O‐03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH

Saved in:
Bibliographic Details
Published inHemaSphere Vol. 6; no. Suppl; pp. 02 - 03
Main Authors M., TELEN, R., BROWN, R., HAGAR, M., IDOWU, I., OSUNKWO, T., KALFA, F., KUYPERS, J., GEIB, P., SCHROEDER, E., WU, P., KELLY, S., SARAF
Format Journal Article
LanguageEnglish
Published Philadelphia, PA Lippincott Williams & Wilkins 16.08.2022
Wiley
Subjects
Oral Presentations
Online AccessGet full text

Cover

More Information
ISSN:2572-9241
2572-9241
DOI:10.1097/01.HS9.0000872820.66998.56